⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104699 | 1.00 | — | — | |
| SCHEMBL798034 | 1.00 | — | — | |
| SCHEMBL17403819 | 0.92 | — | — | |
| SCHEMBL17403818 | 0.92 | — | — | |
| SCHEMBL9883697 | 0.92 | — | — | |
| SCHEMBL14749887 | 0.90 | EPHX1 (0.31) | — | |
| SCHEMBL19565524 | 0.85 | — | — | |
| SCHEMBL19565525 | 0.85 | — | — | |
| SCHEMBL14330213 | 0.85 | — | — | |
| SCHEMBL18419228 | 0.83 | NOS2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11178870-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | MITSUI CHEMICALS AGRO, INC. (JP) | 2021-11-23 | — | — | US | disclosed |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| US-20200338073-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200045968-A1 | PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | MITSUI CHEMICALS AGRO, INC. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7399862-B2 | 5-HT4 receptor agonist compounds | THERAVANCE, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | THERAVANCE, INC. (US) | 2006-05-11 | — | — | US | disclosed |